-
Dade Behring (Deerfield, Illinois), the University of Frankfurt (Frankfurt, Germany) and Innovectis (also Frankfurt) have signed an exclusive license agreement that provides Dade Behring with worldwide rights for the inventions of a research group at the university that relate to placental growth factor (PlGF) for cardiovascular diseases, soluble CD40 ligand for the prognosis of the course of disease in acute coronary syndrome (ACS), and additional markers for cardiovascular diseases.
-
Access managers could benefit by stretching a bit beyond their boundaries and actively seeking participation in the clinical side of health care, suggests Karen McKinley, RN, CHAM, vice president of patient access and care management for Geisinger Health System in Danville, PA.
-
Thirty-six million Americans do not have access to basic health care because they live in communities with an acute shortage of health care providers.
-
The latest survey of 631 providers, payers, companies, and clearinghouses by the Healthcare Information and Management Systems Society (HIMSS) indicates that as of mid-January, only half had completed testing for the Transaction and Code Standards (TCS), which standardized what information must be contained in electronic claims and how it should be transmitted.
-
A security consulting firm that is providing security risk assessment and compliance review services for small health care related businesses says one way to increase incentives for physicians to come into compliance with HIPAA requirements would be for malpractice insurers to offer reduced premiums to those who have done a risk assessment and are moving forward on implementation.
-
-
Hardy ML. What to do about the pain of no more Vioxx? Altern Ther Women's Health 2004;6(11):85-87.
-
-
You are discussing contraceptive options with a patient. When you come to intrauterine devices (IUDs), she dismisses the method and says that it can lead to an ectopic pregnancy. Where did she get such misinformation?
-
This month may well mark a milestone in womens health if the Food and Drug Administration (FDA) follows the recommendation of two of its expert advisory committees to approve the over-the-counter (OTC) sale of Plan B, the levonorgestrel-only emergency contraceptive (EC).
